Investigation of gender heterogeneity in the associations of serum phosphorus with incident coronary artery disease and all-cause mortality

American Journal of Epidemiology

Volumn 169, Issue 1, 2009, Pages 67-77

  Onufrak, Stephen J ^a   Bellasi, Antonio ^b   Cardarelli, Francesca ^b   Vaccarino, Viola ^b   Muntner, Paul ^c   Shaw, Leslee J ^b   Raggi, Paolo ^b  

^a AGRICULTURAL RESEARCH SERVICE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular diseases; Coronary artery disease; Mortality; Phosphorus; Risk; Sex factors

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MINERAL; PHOSPHORUS;

CARDIOVASCULAR DISEASE; HEALTH RISK; METABOLISM; MORTALITY; PHOSPHORUS; RISK FACTOR; SERUM; WOMENS HEALTH;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CONFIDENCE INTERVAL; CORONARY ARTERY; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG METABOLISM; FEMALE; GENDER; GENETIC HETEROGENEITY; HAZARD RATIO; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY FUNCTION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; MORBIDITY; MORTALITY; PATIENT INFORMATION; PATIENT SELECTION; PHOSPHATE BLOOD LEVEL; POPULATION; PROPORTIONAL HAZARDS MODEL; PUBLIC HEALTH; RISK FACTOR; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; UNITED STATES;

AGE FACTORS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CONFIDENCE INTERVALS; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; MISSISSIPPI; MULTIVARIATE ANALYSIS; ODDS RATIO; PHOSPHORUS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; TUNICA INTIMA; TUNICA MEDIA;

EID: 58149269342     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwn285     Document Type: Article

References (32)

1. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16(2):520-528.
2. Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4):607-617.
3. Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44((5 suppl.2)):34-38.
4. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208-2218.
5. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70(4): 771-780.
6. Tonelli M, Sacks F, Pfeffer M, et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005;112(17):2627-2633.
7. Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007;167(9):879-885.
8. Onufrak SJ, Bellasi A, Shaw LJ, et al. Phosphorus levels are associated with subclinical atherosclerosis in the general population. Atherosclerosis. 2008;199(2):424-431.
9. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol. 1989;129(4):687-702.
10. Daly JA, Ertingshausen G. Direct method for determining inorganic phosphate in serum with the "CentrifiChem." Clin Chem. 1972;18(3):263-265.
11. ARIC Coordinating Center. Atherosclerosis Risk in Communities (ARIC) Study. Operations manual no. 10: clinical chemistry determinations. Version 1.0. Chapel Hill, NC: ARIC Coordinating Center, School of Public Health, University of North Carolina, 1987.
12. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247-254.
13. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41(1):47-55.
14. ARIC Coordinating Center. Atherosclerosis Risk in Communities study protocol. Manual 3: surveillance component procedures. Version 4.0. Chapel Hill, NC: ARIC Coordinating Center, School of Public Health, University of North Carolina, 1997.
15. Barnard J, Meng XL. Applications of multiple imputation in medical studies: from AIDS to NHANES. Stat Methods Med Res. 1999;8(1):17-36.
16. Kalantar-Zadeh K, Ikizler TA, Block G, et al. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis. 2003;42(5):864-881.
17. Kalaitzidis R, Tsimihodimos V, Bairaktari E, et al. Disturbances of phosphate metabolism: another feature of metabolic syndrome. Am J Kidney Dis. 2005;45(5):851-858.
18. Burnett-Bowie SM, Mendoza N, Leder BZ. Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men. Bone. 2007;40(4):913-918.
19. Chan CT, Wells H, Kramsch DM. Suppression of calcific fibrous-fatty plaque formation in rabbits by agents not affecting elevated serum cholesterol levels. The effect of thiophene compounds. Circ Res. 1978;43(1):115-125.
20. Eto N, Miyata Y, Ohno H, et al. Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transplant. 2005;20(7):1378-1384.
21. Takahashi Y, Tanaka A, Nakamura T, et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int. 2004;65(3):1099-1104.
22. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345(22):1583-1592.
23. Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87(7):E10-E17.
24. Li X, Yang HY, Giachelli CM. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res. 2006;98(7):905-912.
25. Stubbs JR, Liu S, Tang W, et al. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol. 2007;18(7):2116-2124.
26. Razzaque MS, Sitara D, Taguchi T, et al. Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J. 2006;20(6):720-722.
27. Masuda H, Chikuda H, Suga T, et al. Regulation of multiple ageing-like phenotypes by inducible klotho gene expression in klotho mutant mice. Mech Ageing Dev. 2005;126(12):1274-1283.
28. Kuro-o M. Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism. Curr Opin Nephrol Hypertens. 2006;15(4):437-441.
29. Kurosu H, Yamamoto M, Clark JD, et al. Suppression of aging in mice by the hormone Klotho. Science. 2005;309(5742):1829-1833.
30. Yamamoto M, Clark JD, Pastor JV, et al. Regulation of oxidative stress by the anti-aging hormone klotho. J Biol Chem. 2005;280(45):38029-38034.
31. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31-8.
32. Rickers H, Christiansen C, Christensen P, et al. Serum concentrations of vitamin D metabolites in different degrees of impaired renal function. Estimation of renal and extrarenal secretion rate of 24,25-dihydroxyvitamin D. Nephron. 1985; 39(3):267-71.